EvolveImmune Therapeutics
EvolveImmune Therapeutics: A next-gen immunotherapy company, innovating cancer medicine from Yale research.
Founded
2020EvolveImmune Therapeutics: A next-gen immunotherapy company, innovating cancer medicine from Yale research.
EvolveImmune Therapeutics, founded in Farmington and Branford, CT, is a next-generation immunotherapy company focused on pioneering precision cancer medicines. Originating from research conducted at the Sidi Chen Lab at Yale University, the company leverages a novel in vivo target discovery platform to develop therapies that address CD8 T cell exhaustion in the tumor microenvironment. Their core mission is to deliver superior patient outcomes by selectively regulating mechanisms that drive effective, durable anti-cancer immunity.
Notable affiliated individuals include researchers from Yale University, particularly those from the Sidi Chen Lab. EvolveImmune has achieved significant milestones in validating new pathways essential for overcoming T cell exhaustion, positioning itself as a transformative player in cancer treatment. The company's innovative approach and robust research foundation have made a substantial impact on the field of immunotherapy, offering promising advancements for cancer patients worldwide.
Companies similar to EvolveImmune Therapeutics include Simcha Therapeutics, Repertoire Immune Medicines, Immunitas Therapeutics and Evommune.
EvolveImmune Therapeutics was founded in 2020.
EvolveImmune Therapeutics' headquarters is located in Branford, CT, US.
EvolveImmune Therapeutics' most recent funding round was for $37.4M (USD) in November 2023.
As of Nov 16, 2023, EvolveImmune Therapeutics has disclosed funding of $54.9M (USD). Undisclosed round amounts are excluded.
EvolveImmune Therapeutics has 30 employees as of Feb 4, 2024.
Evommune
evommune.com
